Piper Jaffray analyst David Amsellem says he would not be worried that a generic Xifaxan entrant will emerge prior to the January 2028 launch date outlined in Bausch Health Companies' (BHC) settlement with Teva (TEVA) on its generic filing. The analyst highlights the "relatively complex nature" of Xifaxan and Bausch's "fairly deep intellectual property estate." As such, he continues to believe that visibility into a "durable" EBITDA for Bausch Health is high, with a longer-term annual growth "reaching at least the high single digits." He reiterates an Overweight rating on the shares with a $29 price target.